BR112012015433B8 - composição farmacêutica substancialmente anidra para aplicação cutânea - Google Patents
composição farmacêutica substancialmente anidra para aplicação cutânea Download PDFInfo
- Publication number
- BR112012015433B8 BR112012015433B8 BR112012015433A BR112012015433A BR112012015433B8 BR 112012015433 B8 BR112012015433 B8 BR 112012015433B8 BR 112012015433 A BR112012015433 A BR 112012015433A BR 112012015433 A BR112012015433 A BR 112012015433A BR 112012015433 B8 BR112012015433 B8 BR 112012015433B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- substantially anhydrous
- anhydrous pharmaceutical
- cutaneous application
- cutaneous
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000011877 solvent mixture Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPCT/DK009/000256 | 2009-12-22 | ||
| DK2009000265 | 2009-12-22 | ||
| US29310510P | 2010-01-07 | 2010-01-07 | |
| US61/293105 | 2010-01-07 | ||
| PCT/DK2010/000182 WO2011076207A2 (en) | 2009-12-22 | 2010-12-22 | Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112012015433A2 BR112012015433A2 (pt) | 2016-03-15 |
| BR112012015433B1 BR112012015433B1 (pt) | 2019-04-24 |
| BR112012015433B8 true BR112012015433B8 (pt) | 2020-03-03 |
Family
ID=43618132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012015433A BR112012015433B8 (pt) | 2009-12-22 | 2010-12-22 | composição farmacêutica substancialmente anidra para aplicação cutânea |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20120322776A1 (OSRAM) |
| EP (1) | EP2515865B1 (OSRAM) |
| JP (1) | JP5873439B2 (OSRAM) |
| CN (1) | CN102781425B (OSRAM) |
| AU (1) | AU2010335654B2 (OSRAM) |
| BR (1) | BR112012015433B8 (OSRAM) |
| CA (1) | CA2785251A1 (OSRAM) |
| IL (1) | IL220514A (OSRAM) |
| MX (1) | MX2012007229A (OSRAM) |
| NZ (1) | NZ600999A (OSRAM) |
| RU (1) | RU2560677C2 (OSRAM) |
| WO (1) | WO2011076207A2 (OSRAM) |
| ZA (1) | ZA201204620B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5570442B2 (ja) * | 2011-01-24 | 2014-08-13 | 株式会社シャネル化粧品技術開発研究所 | 水中油型乳化組成物及びその製造方法 |
| CN104822392B (zh) * | 2012-11-30 | 2017-09-08 | 利奥制药有限公司 | 抑制活化的t‑细胞中il‑22表达的方法 |
| EP3084432B1 (en) * | 2013-12-19 | 2018-03-21 | Universiteit Gent | Quantification of glucocorticoids in fish scales, spines, fin rays or otoliths as biomarkers for chronic stress |
| CN104666312B (zh) * | 2015-02-12 | 2017-11-07 | 重庆华邦制药有限公司 | 含有卡泊三醇和二丙酸倍他米松的制剂 |
| CN106265511A (zh) * | 2016-08-22 | 2017-01-04 | 江苏知原药业有限公司 | 一种性能优异的卡泊三醇倍他米松自微乳制剂 |
| CN106265485A (zh) * | 2016-08-22 | 2017-01-04 | 江苏知原药业有限公司 | 一种稳定性改善的卡泊三醇组合物 |
| CN106442841B (zh) * | 2016-12-16 | 2018-09-14 | 上海景峰制药有限公司 | 一种药物中阳离子表面活性剂的分离检测方法 |
| EP3639854A4 (en) | 2017-06-16 | 2021-03-03 | The Doshisha | MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF |
| KR102678365B1 (ko) * | 2018-03-20 | 2024-06-26 | 재단법인 경기도경제과학진흥원 | 콜레칼시페롤의 가용화 조성물 및 그 제조방법 |
| EP3741378A1 (de) | 2019-05-23 | 2020-11-25 | Dimitrios Tsakouridis | Zusammensetzung zur topischen behandlung und pflege der psoriatischen haut |
| CA3091554A1 (en) * | 2020-08-28 | 2022-02-28 | Triple Hair Inc. | Formulations for reducing hair loss and/or increasing hair regrowth |
| JP7633712B2 (ja) * | 2023-05-12 | 2025-02-20 | アピ株式会社 | 外用組成物 |
| JP2024163642A (ja) * | 2023-05-12 | 2024-11-22 | アピ株式会社 | 外用組成物 |
| CN118304279B (zh) * | 2024-03-27 | 2025-04-25 | 青岛双鲸药业股份有限公司 | 一种骨化三醇自微乳口溶膜及其制备方法 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2753377B1 (fr) * | 1996-09-19 | 1999-09-24 | Rhone Merieux | Nouvelle association parasiticide a base de 1-n-phenylpyra- zoles et de lactones macrocycliques endectocides |
| US5639724A (en) * | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
| JP2655190B2 (ja) * | 1989-06-21 | 1997-09-17 | エスエス製薬 株式会社 | コルチコステロイド含有軟膏剤 |
| AU667316B2 (en) * | 1991-07-26 | 1996-03-21 | Smithkline Beecham Corporation | W/O microemulsions |
| US5766628A (en) * | 1992-02-24 | 1998-06-16 | Merz + Co. Gmbh & Co. | Bath and shower composition having vesicle-forming properties and method for the production and use thereof |
| US5763426A (en) | 1993-01-15 | 1998-06-09 | Leo Pharmaceutical Products Ltd. | Crystalline form of a vitamin D analogue |
| WO1994023749A1 (fr) | 1993-04-19 | 1994-10-27 | Institute For Advanced Skin Research Inc. | Preparation en microemulsion contenant une substance difficilement absorbable |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| GB9602111D0 (en) * | 1996-02-02 | 1996-04-03 | Unilever Plc | Personal care composition |
| GB9611603D0 (en) * | 1996-06-04 | 1996-08-07 | Leo Pharm Prod Ltd | Chemical compounds |
| KR20010032892A (ko) * | 1997-12-09 | 2001-04-25 | 나가야마 오사무 | 비타민 ｄ３유도체를 함유하는 크림제 |
| US5989531A (en) * | 1998-11-13 | 1999-11-23 | Colgate-Palmolive Company | Antiperspirant formulation for porous applicator |
| GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6582683B2 (en) * | 2000-01-04 | 2003-06-24 | Skinvisible Pharmaceuticals, Inc. | Dermal barrier composition |
| DK1331927T3 (da) * | 2000-10-27 | 2008-05-05 | Leo Pharma As | Topisk komposition der indeholder mindst et D-vitamin eller en D-vitamin analog og mindst et kosttikosteroid |
| US7005557B2 (en) * | 2001-07-03 | 2006-02-28 | The Procter & Gamble Company | Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| IL164163A0 (en) * | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
| US20060189586A1 (en) * | 2003-06-11 | 2006-08-24 | Cleland Jeffrey L | Pharmaceutical compositions comprising active vitamin D compounds |
| BRPI0411341A (pt) * | 2003-06-17 | 2006-07-11 | Du Pont | proteìnas modificadas da soja em composições para enrijecimento da pele |
| ZA200510137B (en) | 2003-07-24 | 2007-04-25 | Leo Pharma As | Novel aminobenzophenone compounds |
| US8795693B2 (en) * | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US20090105336A1 (en) * | 2004-04-19 | 2009-04-23 | Strategic Science & Technologies, Llc | Beneficial Effects of Increasing Local Blood Flow |
| CA2567683A1 (en) * | 2004-06-17 | 2005-12-29 | Galderma S.A. | Composition in spray form comprising a combination of a corticoid and a vitamin d derivative in an oily phase |
| FR2871694B1 (fr) * | 2004-06-17 | 2008-07-04 | Galderma Sa | Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises |
| KR101260236B1 (ko) | 2004-12-13 | 2013-05-06 | 레오 파마 에이/에스 | 트리아졸 치환된 아미노벤조페논 화합물 |
| EP1827297A1 (en) * | 2004-12-23 | 2007-09-05 | Unilever Plc | Water-in-oil emulsions for hair treatment |
| CA2608021A1 (en) * | 2005-05-10 | 2006-11-16 | Dermipsor Ltd. | Compositions and methods for skin care |
| CA2612408A1 (en) * | 2005-06-15 | 2006-12-28 | Apollo Pharmaceutical, Inc. | Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis |
| FR2887150B1 (fr) * | 2005-06-17 | 2007-08-03 | Galderma Res & Dev | Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise |
| US20070249055A1 (en) * | 2006-04-24 | 2007-10-25 | The Procter & Gamble Company | Method of measuring lotion and additive ingredient transfer |
| US20080260655A1 (en) * | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| FR2909284B1 (fr) * | 2006-11-30 | 2012-09-21 | Galderma Sa | Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien |
| AU2007336538B2 (en) | 2006-12-22 | 2012-04-05 | Leo Pharma A/S | Substituted acetophenones useful as PDE4 inhibitors |
| KR101571654B1 (ko) | 2007-02-28 | 2015-11-25 | 레오 파마 에이/에스 | 신규한 포스포디에스테라제 억제제 |
| EP1970049A1 (en) * | 2007-03-15 | 2008-09-17 | Drug Delivery Solutions Limited | Polyaphron topical composition with vitamin D and corticosteroid |
| US20100099710A1 (en) | 2007-04-19 | 2010-04-22 | Lene Jensen | Src family kinase inhibitors |
| HRP20231142T3 (hr) * | 2007-04-25 | 2024-01-05 | Eirgen Pharma Ltd. | Kontrolirano oslobađanje 25-hidroksivitamina d |
| US20100189674A1 (en) | 2007-05-11 | 2010-07-29 | Sonneborn Inc. | Petrolatum Having Silicone-Like Properties |
| US20080299156A1 (en) * | 2007-06-01 | 2008-12-04 | L'oreal | Skin care compositions containing a high internal phase emulsion |
| SG172206A1 (en) | 2008-12-19 | 2011-07-28 | Leo Pharma As | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases |
| JP2012531393A (ja) * | 2009-06-29 | 2012-12-10 | グラクソ グループ リミテッド | 新規の医学的使用 |
-
2010
- 2010-12-22 AU AU2010335654A patent/AU2010335654B2/en active Active
- 2010-12-22 CN CN201080063418.7A patent/CN102781425B/zh active Active
- 2010-12-22 JP JP2012545090A patent/JP5873439B2/ja active Active
- 2010-12-22 RU RU2012130421/15A patent/RU2560677C2/ru active
- 2010-12-22 CA CA2785251A patent/CA2785251A1/en not_active Abandoned
- 2010-12-22 WO PCT/DK2010/000182 patent/WO2011076207A2/en not_active Ceased
- 2010-12-22 US US13/518,320 patent/US20120322776A1/en not_active Abandoned
- 2010-12-22 NZ NZ600999A patent/NZ600999A/en unknown
- 2010-12-22 MX MX2012007229A patent/MX2012007229A/es active IP Right Grant
- 2010-12-22 EP EP10803218.6A patent/EP2515865B1/en active Active
- 2010-12-22 BR BR112012015433A patent/BR112012015433B8/pt active IP Right Grant
-
2012
- 2012-06-19 IL IL220514A patent/IL220514A/en active IP Right Grant
- 2012-06-21 ZA ZA2012/04620A patent/ZA201204620B/en unknown
-
2016
- 2016-07-19 US US15/214,216 patent/US20160324875A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2785251A1 (en) | 2011-06-30 |
| RU2012130421A (ru) | 2014-01-27 |
| EP2515865A2 (en) | 2012-10-31 |
| JP5873439B2 (ja) | 2016-03-01 |
| US20120322776A1 (en) | 2012-12-20 |
| WO2011076207A3 (en) | 2012-03-01 |
| CN102781425B (zh) | 2014-08-13 |
| BR112012015433B1 (pt) | 2019-04-24 |
| BR112012015433A2 (pt) | 2016-03-15 |
| AU2010335654A1 (en) | 2012-07-26 |
| WO2011076207A2 (en) | 2011-06-30 |
| CN102781425A (zh) | 2012-11-14 |
| US20160324875A1 (en) | 2016-11-10 |
| HK1177899A1 (en) | 2013-08-30 |
| JP2013515018A (ja) | 2013-05-02 |
| IL220514A (en) | 2017-01-31 |
| NZ600999A (en) | 2014-06-27 |
| AU2010335654B2 (en) | 2015-04-09 |
| MX2012007229A (es) | 2012-07-30 |
| RU2560677C2 (ru) | 2015-08-20 |
| ZA201204620B (en) | 2013-09-25 |
| EP2515865B1 (en) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012015433B8 (pt) | composição farmacêutica substancialmente anidra para aplicação cutânea | |
| CO6680667A2 (es) | Derivados ester de ácido borónico cíclico y sus usos terapéuticos | |
| DOP2013000105A (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis | |
| MY167691A (en) | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid | |
| MX388946B (es) | Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos. | |
| BR112012008823B8 (pt) | compostos que modulam receptor de androgênio, composição farmacêutica compreendendo os ditos compostos e usos dos mesmos para a prevenção ou tratamento de distúrbios dependentes de receptores de androgênio | |
| BR112012021086A2 (pt) | composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos | |
| PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
| BR112015032623A2 (pt) | composto, composição farmacêutica, métodos para tratar doenças e condições, e para degradar o receptor de estrogênio, usos de um composto e de uma combinação, e, combinação | |
| UY33776A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| BR112012006686B8 (pt) | compostos de amida substituída, composições farmacêuticas contendo os ditos compostos, e uso dos mesmos para prevenir e/ou tratar doenças causadas pelo lpa | |
| MX2011009847A (es) | Agentes antihelminticos y su uso. | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| SMT201200017B (it) | Nuovi antagonisti P2X7R e il loro uso. | |
| BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
| ES2408343R1 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| EP2515912A4 (en) | PHARMACEUTICAL COMPOSITION WITH VITAMIN D ANALOGON AND COLOSTERS-TENSID MIXTURE | |
| BR112012015437A2 (pt) | composição tópica substancialmente anidra de armazenamento estável | |
| EP2361083A4 (en) | COMPOSITION FOR THE TREATMENT OF EPITHELIAL TISSUE | |
| AR077490A1 (es) | Composiciones farmaceuticas topicas para el tratamiento de una condicion hiperproliferativa de la piel | |
| ECSP15003613A (es) | Formulación transdérmica que contiene inhibidores de cox | |
| CL2010001577A1 (es) | Uso de nifurtimox para preparar un medicamento util en el tratamiento de enfermedades causadas por giardias. | |
| CL2015001502A1 (es) | Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma. | |
| BR112013000296A2 (pt) | agentes terapêuticos 976 | |
| AR102008A1 (es) | Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2010, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant |
Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO A PRIORIDADE UNIONISTA. |